Biotech in OKC: driven by discoveryPublished: Wednesday, October 28, 2020 By: Chamber Staff Source: VeloCity
The bioscience industry of discovery has discovered the Oklahoma Medical Research Foundation (OMRF). Given its exciting findings and the remarkable array of resources it offers the pharmaceutical world, the institution has long since transcended its Oklahoma roots - i.e. the ‘O’ in OMRF.
One of the latest examples of OMRF’s far-reaching impact is a prestigious agreement with the pharmaceutical maker GSK (GlaxoSmithKline) in London. As part of its program to connect with international academia’s most promising investigations, the British GSK seized the opportunity to collaborate with OMRF’s Dr. Charles Esmon and his team, which includes Xiaomei Zhang, Ph.D. and Jun Xu, Ph.D. What brought GSK to OKC? The promise of preventing organ damage and death caused by acute conditions like pancreatitis, lung injury and trauma – based on the discoveries of Esmon and his colleagues at OMRF.
Of course, OMRF’s new collaborative partner, GlaxoSmithKline, has likewise grown well beyond its “G” stage and succumbed to mere initials.
Glaxo dates back to 1873 in Bunnythorpe, New Zealand. With the 2000 merger of Glaxo Wellcom with SmithKline, the brand became GSK.
Read the full story on VeloCityOKC.com.